513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Powell Industries reported fiscal fourth-quarter and full-year 2024 results for the period ended September 30, 2024, with revenue and net income up sharply from the prior year. Q4 revenue was down 5% from the third quarter, and full-year net new orders fell to $1.1 billion from $1.4 billion. The filing gives no numeric fiscal 2025 guidance; management only said it expects fiscal 2025 to be another successful year.
Q4 revenue of $275 million, up 32% from $208.6 million; diluted EPS of $3.77 vs. $2.17 a year earlier
Full-year revenue of $1.0 billion, up 45%; net income of $149.8 million, or $12.29 per diluted share, up 175%
Backlog of $1.3 billion at September 30, 2024, essentially unchanged from June 30, 2024 and September 30, 2023
Conference call scheduled for Wednesday, November 20, 2024 at 11:00 a.m. Eastern time
StoneX Group reported fiscal fourth-quarter 2024 results, with net income of $76.7 million, up 51%, and diluted EPS of $2.32, up 48%, for the quarter ended September 30, 2024. For the full fiscal year, net income rose 9% to $260.8 million and diluted EPS rose 7% to $7.96, which the company called a record annual result. Results were strong across most segments, though the company noted relatively low market volatility.
Q4 net operating revenues rose 13% to $454.8 million; quarterly net income was $76.7 million, up 51% from $50.7 million a year earlier
Quarterly diluted EPS was $2.32 versus $1.57 a year earlier; ROE was 18.5% for the quarter
Full-year net income was $260.8 million, up 9%; full-year diluted EPS was $7.96, up 7%
Institutional segment operating revenues rose 30% to $554.1 million in the quarter; OTC derivatives operating revenues fell 23%
Dolby reported fourth-quarter fiscal 2024 revenue of $305 million, up from $291 million a year earlier, and GAAP diluted earnings of $0.61 per share versus $0.09. For the full fiscal year, revenue fell to $1.27 billion from $1.30 billion, while GAAP diluted EPS rose to $2.69 from $2.05. The company also gave fiscal 2025 revenue guidance of $1.33 billion to $1.39 billion and entered a $250 million revolving credit facility with Bank of America, with no amount drawn at closing.
Q4 fiscal 2024 revenue $305 million vs. $291 million a year earlier; GAAP diluted EPS $0.61 vs. $0.09
Full fiscal 2024 revenue $1.27 billion vs. $1.30 billion; GAAP diluted EPS $2.69 vs. $2.05
Fiscal 2025 guidance: total revenue $1.33 billion to $1.39 billion; GAAP diluted EPS $2.43 to $2.58
Credit Agreement signed November 14, 2024: $250 million unsecured revolver plus $150 million uncommitted incremental capacity; $0.33 per share dividend payable December 10, 2024
Jacobs reported fiscal fourth-quarter 2024 revenue of $3.0 billion, up 4.4% year over year, and GAAP EPS of $2.38, helped by $187 million in mark-to-market gains on its Amentum stock. The company also gave fiscal 2025 guidance for adjusted EPS of $5.80-$6.20, compared with fiscal 2024 adjusted EPS of $5.28, following the completed separation of its Critical Mission Solutions and Cyber & Intelligence businesses into Amentum.
Q4 revenue of $2,960,150 thousand, up 4.4%; adjusted net revenue of $2.1 billion, up 4.3%
Q4 GAAP EPS of $2.38 versus $0.63 a year earlier; adjusted EPS of $1.37, up 28.0%
FY2025 outlook: adjusted EPS of $5.80-$6.20, adjusted EBITDA margin of 13.8-14.0%
FY2024 returned $545 million to shareholders through dividends and share repurchases
Cytokinetics granted Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan under an agreement signed November 18, 2024. Cytokinetics will receive a €50 million upfront payment, with additional milestone and royalty payments possible, while it keeps the right to run certain clinical trials in Japan.
Upfront payment of €50 million from Bayer
Milestone payments of up to €90 million tied to clinical and launch events in hypertrophic cardiomyopathy
Commercial milestones of up to €490 million plus tiered royalties on Japan net sales, from the high teens to the low thirties percent
Agreement dated November 18, 2024; full text to be filed with the 2024 Form 10-K
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.